BEGIN ARTICLE PREVIEW:
The transatlantic biotech ADC Therapeutics is getting a speedy review for its anti-body drug conjugate loncastuximab tesirine (Lonca), developed for relapsed or refractory diffuse large B-cell lymphoma.
Chris Martin ADC
ADC $ADCT said Friday morning that the FDA put their drug on the fast lane, providing a priority review for the drug with a May 21 PDUFA date. The biotech won over regulators with Phase II data that reflected an overall response rate of 48.3% (70/145 patients) and a complete response rate of 24.1%.
“The FDA’s acceptance of our BLA and granting of priority review for Lonca is a tremendous accomplishment that brings ADC Therapeutics one step closer to being able to offer patients with relapsed or refractory DLBCL a greatly needed new treatment option in 2021,” said ADC chief Chris …
END ARTICLE PREVIEW